Pill Identifier App

Dr. Gabriel Sosne Presents TB4 Anti-inflammation Data at ARVO

BETHESDA, Md.--(BUSINESS WIRE)--Apr 29, 2008 - REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that Dr. Gabriel Sosne, Assistant Professor of Ophthalmology at Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, MI, presented data from a study entitled, "Lipid Rafts and Actin Are Important for Thymosin Beta 4-Mediated Anti-Inflammatory Effects in the Cornea," at the Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. This work continues to define the anti-inflammatory mechanisms of TB4 that have been reported by Dr. Sosne and others in numerous in vitro and in vivo studies in the eye, skin, and heart.

"Today there is nothing available, pharmacologically, that stimulates wound healing in the cornea. In cases of damage related to diabetes or alkaline exposure, treatments have focused on creating an environment conducive to healing and Thymosin Beta 4 could play an important role. Further, in light of recent information on post-operative LASIK complications, it would be very interesting to evaluate TB4's impact on healing after LASIK, as well as on some of the other reported complications related to this surgery," explained Dr. Sosne. Dr. Sosne is a member of RegeneRx's Medical and Scientific Advisory Board and holds stock options related thereto.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular wound healing, respectively. These product candidates are based on TB4, a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to its technology and is currently sponsoring three Phase II chronic dermal wound healing clinical trials, a Phase II ophthalmic wound healing clinical trial, and a Phase IA parenteral clinical trial supporting systemic delivery of RGN-352 for cardiovascular indications.

RegeneRx Technology Backgrounder

TB4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. RegeneRx has identified several molecular variations of TB4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U.S., have published numerous scientific articles indicating TB4's in vitro and in vivo efficacy in accelerating wound healing and tissue protection under a variety of conditions. Abstracts of scientific papers related to TB4's mechanisms of action may be viewed at RegeneRx's web page: www.regenerx.com.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Examples of such forward-looking statements include statements concerning the therapeutic potential of TB4 for ophthalmic wounds and/or LASIK complications. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that although TB4 has demonstrated potential therapeutic benefit for ophthalmic wounds, the Company's product candidates may not demonstrate safety and/or efficacy in clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that the company's or its collaborators will not obtain approval to market the company's product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborators for the funding or conduct of further development and commercialization activities relating to the Company's product candidates, and such other risks described in the company's annual report on Form 10-K, and other filings the company makes with the SEC. Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

RegeneRx Biopharmaceuticals, Inc.
J.J. Finkelstein, 301-280-1992
jjfnk@regenerx.com

Posted: April 2008

View comments

Hide
(web3)